News | July 28, 2021
Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated
